Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: Examination of trametinib responses in cultured breast cancer lines

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Leung, Euphemia Y ^a   Kim, Ji Eun ^a,b   Askarian Amiri, Marjan ^a   Rewcastle, Gordon W ^a   Finlay, Graeme J ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DACTOLISIB; EVEROLIMUS; GSK 2126458; MITOGEN ACTIVATED PROTEIN KINASE; OMIPALISIB; TAMOXIFEN; TRAMETINIB; UNCLASSIFIED DRUG; 2,4-DIFLUORO-N-(2-(METHYLOXY)-5-(4-(4-PYRIDAZINYL)-6-QUINOLINYL)-3-PYRIDINYL)BENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; QUINOLINE DERIVATIVE; RAPAMYCIN; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; PREDICTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG EFFECTS; FEMALE; IC50; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; PYRIMIDINONES; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84932156996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105792     Document Type: Article

References (42)

1. Montagut C, Settleman J (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134.
2. Baselga J (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16 Suppl 1: 12-19.
3. Thomas RS, Sarwar N, Phoenix F, Coombes RC, Ali S (2008) Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptoralpha activity. J Mol Endocrinol 40: 173-184. (Pubitemid 351586826)
4. Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, et al. (2010) Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 126: 545-562.
5. Gee JM, Robertson JF, Ellis IO, Nicholson RI (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254. (Pubitemid 32592092)
6. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247.
7. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, et al. (2002) Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747-1753. (Pubitemid 34633730)
8. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, et al. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456-4462. (Pubitemid 41185111)
9. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, et al. (2010) Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16: 3670-3683.
10. Nazarian RM, Prieto VG, Elder DE, Duncan LM (2010) Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol 37 Suppl 1: 41-47.
11. Stones CJ, Kim JE, Joseph WR, Leung E, Marshall ES, et al. (2013) Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet 4: 66.
12. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, et al. (2013) Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31: 482-489.
13. Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, et al. (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11: 720-729.
14. Menzies AM, Long GV (2014) Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res 20: 2035-2043.
15. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, et al. (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17: 989-1000.
16. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529.
17. Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, et al. (2010) Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett 1: 39-43.
18. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
19. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVPBEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
20. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M (2007) Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5: 195-201. (Pubitemid 46424000)
21. Valentino JD, Li J, Zaytseva YY, Mustain WC, Elliott VA, et al. (2014) Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors. Clin Cancer Res 20: 1212-1222.
22. Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106: 1386-1394.
23. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
24. Leung E, Kannan N, Krissansen GW, Findlay MP, Baguley BC (2010) MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 9: 717-724.
25. Whitehead RH, Monaghan P, Webber LM, Bertoncello I, Vitali AA (1983) A new human breast carcinoma cell line (PMC42) with stem cell characteristics. II. Characterization of cells growing as organoids. J Natl Cancer Inst 71: 1193- 1203.
26. Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC (2011) Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther 11: 938-946.
27. Leung E, Rewcastle GW, Joseph WR, Rosengren RJ, Larsen L, et al. (2012) Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells. Invest New Drugs 30: 2103-2112.
28. Leung E, Kim JE, Askarian-Amiri M, Finlay GJ, Baguley BC (2014) Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population. BioMed Res Int 2014: 7.
29. Garcia-Echeverria C, Stauffer F, Furet P (2006) Preparation of imidazo[4,5- c]quinolin-2-ones and -thiones as lipid, PI3 and/or DNA protein kinase inhibitors with therapeutic uses. PCT Int Appl WO 2006122806 A2.
30. Stowasser F, Baenziger M, Garad SD (2008) Preparation of salts and crystalline forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3- dihydroimidazo[4,5- c]quinolin-1-yl)-phenyl]propionitrile and its use as a drug. PCT Int Appl WO 2008064093A2.
31. Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, et al. (2000) Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 60: 5340-5344.
32. Corcoran RB, Settleman J, Engelman JA (2011) Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2: 336-346.
33. Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A (2010) PI3K/ Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 22: 1369-1378.
34. Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, et al. (2009) Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther 329: 1063- 1070.
35. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, et al. (2012) High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 17: 766-774.
36. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, et al. (2013) Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 39: 935-946.
37. Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A (2008) Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 7: 307- 315.
38. Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13: 140-156.
39. Larsen KB, Lamark T, Overvatn A, Harneshaug I, Johansen T, et al. (2010) A reporter cell system to monitor autophagy based on p62/SQSTM1. Autophagy 6: 784-793.
40. Radhakrishnan P, Baraneedharan U, Veluchamy S, Dhandapani M, Pinto DD, et al. (2013) Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers. Cancer Res 73: 1118-1127.
41. Kim JE, Stones C, Joseph WR, Leung E, Finlay GJ, et al. (2012) Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer 12: 141.
42. Kuntzer J, Maisel D, Lenhof HP, Klostermann S, Burtscher H (2011) The Roche Cancer Genome Database 2.0. BMC Med Genomics 4: 43.